DEVELOPMENT OF VACCINES BASED ON ADENOVIRAL VECTORS: A REVIEW OF FOREIGN CLINICAL STUDIES (PART 2)

Currently, many human infectious diseases do not developed effective methods of treatment and prevention. One of the latest successes of biotechnology is the use of adenoviral vectors carrying immunodominant antigens of various pathogens as genetically engineered vaccines both preventive and ther...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	L. V. Cherenova, T. V. Kashtigo, Kh. S. Saiadian, M. M. Shmarov
Formato:	article
Lenguaje:	RU
Publicado:	SPb RAACI 2017
Materias:	adenoviral vector vaccine clinical trials infectious diseases human adenovirus chimpanzee adenovirus Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/873ea27afa2e4dde939b3d79061df97c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:873ea27afa2e4dde939b3d79061df97c
record_format	dspace
spelling	oai:doaj.org-article:873ea27afa2e4dde939b3d79061df97c2021-11-18T08:03:46ZDEVELOPMENT OF VACCINES BASED ON ADENOVIRAL VECTORS: A REVIEW OF FOREIGN CLINICAL STUDIES (PART 2)1563-06252313-741X10.15789/1563-0625-2017-4-329-358https://doaj.org/article/873ea27afa2e4dde939b3d79061df97c2017-08-01T00:00:00Zhttps://www.mimmun.ru/mimmun/article/view/1307https://doaj.org/toc/1563-0625https://doaj.org/toc/2313-741XCurrently, many human infectious diseases do not developed effective methods of treatment and prevention. One of the latest successes of biotechnology is the use of adenoviral vectors carrying immunodominant antigens of various pathogens as genetically engineered vaccines both preventive and therapeutic. The use of genetic engineering technologies allows not to use in the manufacture of vaccines live viruses and bacteria, reduces the time needed for vaccine creation and production of new vaccines. Adenoviral vectors naturally penetrate into human cells, causing a rather long and significant both humoral and cellular immune response. In the second part of review, we provide information about the ongoing worldwide clinical trials of adenoviral vector-based vaccines against various infectious diseases such as influenza, malaria, Ebola haemorrhagic fever, tuberculosis, hepatitis and several others, like as to consider selection parameters of volunteers, vaccination schedule, doses of drug administration, results of completed experiments, and preliminary data on currently ongoing research.L. V. CherenovaT. V. KashtigoKh. S. SaiadianM. M. ShmarovSPb RAACIarticleadenoviral vectorvaccineclinical trialsinfectious diseaseshuman adenoviruschimpanzee adenovirusImmunologic diseases. AllergyRC581-607RUMedicinskaâ Immunologiâ, Vol 19, Iss 4, Pp 329-358 (2017)
institution	DOAJ
collection	DOAJ
language	RU
topic	adenoviral vector vaccine clinical trials infectious diseases human adenovirus chimpanzee adenovirus Immunologic diseases. Allergy RC581-607
spellingShingle	adenoviral vector vaccine clinical trials infectious diseases human adenovirus chimpanzee adenovirus Immunologic diseases. Allergy RC581-607 L. V. Cherenova T. V. Kashtigo Kh. S. Saiadian M. M. Shmarov DEVELOPMENT OF VACCINES BASED ON ADENOVIRAL VECTORS: A REVIEW OF FOREIGN CLINICAL STUDIES (PART 2)
description	Currently, many human infectious diseases do not developed effective methods of treatment and prevention. One of the latest successes of biotechnology is the use of adenoviral vectors carrying immunodominant antigens of various pathogens as genetically engineered vaccines both preventive and therapeutic. The use of genetic engineering technologies allows not to use in the manufacture of vaccines live viruses and bacteria, reduces the time needed for vaccine creation and production of new vaccines. Adenoviral vectors naturally penetrate into human cells, causing a rather long and significant both humoral and cellular immune response. In the second part of review, we provide information about the ongoing worldwide clinical trials of adenoviral vector-based vaccines against various infectious diseases such as influenza, malaria, Ebola haemorrhagic fever, tuberculosis, hepatitis and several others, like as to consider selection parameters of volunteers, vaccination schedule, doses of drug administration, results of completed experiments, and preliminary data on currently ongoing research.
format	article
author	L. V. Cherenova T. V. Kashtigo Kh. S. Saiadian M. M. Shmarov
author_facet	L. V. Cherenova T. V. Kashtigo Kh. S. Saiadian M. M. Shmarov
author_sort	L. V. Cherenova
title	DEVELOPMENT OF VACCINES BASED ON ADENOVIRAL VECTORS: A REVIEW OF FOREIGN CLINICAL STUDIES (PART 2)
title_short	DEVELOPMENT OF VACCINES BASED ON ADENOVIRAL VECTORS: A REVIEW OF FOREIGN CLINICAL STUDIES (PART 2)
title_full	DEVELOPMENT OF VACCINES BASED ON ADENOVIRAL VECTORS: A REVIEW OF FOREIGN CLINICAL STUDIES (PART 2)
title_fullStr	DEVELOPMENT OF VACCINES BASED ON ADENOVIRAL VECTORS: A REVIEW OF FOREIGN CLINICAL STUDIES (PART 2)
title_full_unstemmed	DEVELOPMENT OF VACCINES BASED ON ADENOVIRAL VECTORS: A REVIEW OF FOREIGN CLINICAL STUDIES (PART 2)
title_sort	development of vaccines based on adenoviral vectors: a review of foreign clinical studies (part 2)
publisher	SPb RAACI
publishDate	2017
url	https://doaj.org/article/873ea27afa2e4dde939b3d79061df97c
work_keys_str_mv	AT lvcherenova developmentofvaccinesbasedonadenoviralvectorsareviewofforeignclinicalstudiespart2 AT tvkashtigo developmentofvaccinesbasedonadenoviralvectorsareviewofforeignclinicalstudiespart2 AT khssaiadian developmentofvaccinesbasedonadenoviralvectorsareviewofforeignclinicalstudiespart2 AT mmshmarov developmentofvaccinesbasedonadenoviralvectorsareviewofforeignclinicalstudiespart2
_version_	1718422363596390400

DEVELOPMENT OF VACCINES BASED ON ADENOVIRAL VECTORS: A REVIEW OF FOREIGN CLINICAL STUDIES (PART 2)

Ejemplares similares